Methods of treating ulcerative colitis
Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human α4β7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
1. A method for achieving mucosal healing and maintaining clinical remission in a human patient having moderately to severely active ulcerative colitis, comprising intravenously administering a clinically proven effective dose of 300 mg of an antibody that has binding specificity for human α4β7 integrin every eight weeks, wherein the antibody comprises the heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:2, and the light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:4, and wherein mucosal healing is achieved and clinical remission is maintained, and mucosal healing is defined as an endoscopic subscore of 1 point or less.
2. The method of claim 1 , wherein the heavy chain of the antibody comprises amino acids 20 to 470 of SEQ ID NO:2, and the light chain of the antibody comprises amino acids 20 to 238 of SEQ ID NO:4.
3. The method of claim 1 , wherein each dose is intravenously administered as an infusion over about 30 minutes.
4. The method of claim 1 , wherein the human patient had a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist.
5. A method for achieving mucosal healing and maintaining clinical remission in a human patient having moderately to severely active ulcerative colitis, comprising intravenously administering a clinically proven effective dose of 300 mg of vedolizumab every eight weeks,
wherein mucosal healing is achieved and clinical remission is maintained, and mucosal healing is defined as an endoscopic subscore of 1 point or less.